company background image
SABS logo

SAB Biotherapeutics NasdaqCM:SABS Stock Report

Last Price

US$3.07

Market Cap

US$28.2m

7D

-17.0%

1Y

-67.3%

Updated

21 Nov, 2024

Data

Company Financials +

SAB Biotherapeutics, Inc.

NasdaqCM:SABS Stock Report

Market Cap: US$28.2m

SABS Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. More details

SABS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 16.6% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

+ 3 more risks

SAB Biotherapeutics, Inc. Competitors

vTv Therapeutics

NasdaqCM:VTVT

US$46.5m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Shattuck Labs

NasdaqGS:STTK

US$53.0m

I-Mab

NasdaqGM:IMAB

US$77.6m

Price History & Performance

Summary of all time highs, changes and price drops for SAB Biotherapeutics
Historical stock prices
Current Share PriceUS$3.07
52 Week HighUS$9.72
52 Week LowUS$2.16
Beta0.64
11 Month Change7.72%
3 Month Change15.41%
1 Year Change-67.34%
33 Year Change-96.55%
5 Year Changen/a
Change since IPO-96.98%

Recent News & Updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Recent updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

Shareholder Returns

SABSUS BiotechsUS Market
7D-17.0%-6.5%-1.0%
1Y-67.3%14.6%30.3%

Return vs Industry: SABS underperformed the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: SABS underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is SABS's price volatile compared to industry and market?
SABS volatility
SABS Average Weekly Movement18.3%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: SABS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SABS's weekly volatility has increased from 13% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201457Samuel Reichwww.sabbiotherapeutics.com

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.

SAB Biotherapeutics, Inc. Fundamentals Summary

How do SAB Biotherapeutics's earnings and revenue compare to its market cap?
SABS fundamental statistics
Market capUS$28.24m
Earnings (TTM)-US$45.57m
Revenue (TTM)US$1.51m

18.7x

P/S Ratio

-0.6x

P/E Ratio

Is SABS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SABS income statement (TTM)
RevenueUS$1.51m
Cost of RevenueUS$26.90m
Gross Profit-US$25.38m
Other ExpensesUS$20.18m
Earnings-US$45.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.94
Gross Margin-1,678.08%
Net Profit Margin-3,012.27%
Debt/Equity Ratio0%

How did SABS perform over the long term?

See historical performance and comparison